Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7 vs 14 Days of Antibiotics for Graft Pyelonephritis in Kidney Transplant Recipients (KTI)
2025-523120-53-00Phase 4Authorised
- Sponsor
- Bellvitge University Hospital
- Start
- Mar 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ciprofloxacin and ceftriaxone in Acute graft pyelonephritis (AGPN) and infection in kidney transplant recipients (2 arms), sponsored by Bellvitge University Hospital. Primary endpoint: Primary composite endpoint at 90 days. Planned start Mar 2026; status: authorised.
02
Drugs
ciprofloxacinceftriaxone
03
Conditions
Acute graft pyelonephritis (AGPN)infection in kidney transplant recipients
Beyond the preview
Go deeper on 2025-523120-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523120-53-00.